Tags

Type your tag names separated by a space and hit enter

Role for fibrate therapy in diabetes: evidence before FIELD.
Curr Opin Lipidol 2005; 16(6):648-51CO

Abstract

PURPOSE OF REVIEW

Diabetic dyslipidaemia, among the main factors contributing to vascular risk in type 2 diabetes, is characterized by hypertriglyceridaemia, low HDL-cholesterol and increased prevalence of small dense LDL particles. Because fibrates have positive effects on triglycerides, HDL-cholesterol and LDL particle size, they may be an appropriate treatment for diabetic dyslipidaemia. Statins have been shown to diminish significantly the risk for coronary disease in patients with type 2 diabetes, and so what are the real effects of fibrates on cardiovascular risk in type 2 diabetes?

RECENT FINDINGS

Although statins reduce the incidence of coronary disease in type 2 diabetes, data from clinical trials demonstrate 'residual' cardiovascular risk in these patients treated with statins. Clinical trials with fibrates show that they are particularly effective in reducing cardiovascular risk in patients with type 2 diabetes/metabolic syndrome and in those exhibiting the lipid abnormalities typical of diabetic dyslipidaemia (elevated triglycerides, low HDL-cholesterol).

SUMMARY

Data on the effects of fibrates on cardiovascular risk in diabetes were obtained from subgroup analyses. Thus far, the only study performed specifically in patients with type 2 diabetes is the angiographic Diabetes Atherosclerosis Intervention Study which demonstrated a significant reduction in progression of atherosclerosis in patients receiving fenofibrate, but it was not powered to analyse the effects of fibrates on clinical outcomes. This is why the Fenofibrate Intervention and Event Lowering in Diabetes study is needed; it will provide robust data on the ability of fibrates to reduce cardiovascular risk in patients with type 2 diabetes.

Authors+Show Affiliations

Service Endocrinologie, Diabétologie et Maladies Métaboliques, Centre Hospitalier, Universitaire de Dijon, and INSERM U498, Faculté de Médecine, Dijon, France. bruno.verges@chu-dijon.fr

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

16276243

Citation

Vergès, Bruno. "Role for Fibrate Therapy in Diabetes: Evidence Before FIELD." Current Opinion in Lipidology, vol. 16, no. 6, 2005, pp. 648-51.
Vergès B. Role for fibrate therapy in diabetes: evidence before FIELD. Curr Opin Lipidol. 2005;16(6):648-51.
Vergès, B. (2005). Role for fibrate therapy in diabetes: evidence before FIELD. Current Opinion in Lipidology, 16(6), pp. 648-51.
Vergès B. Role for Fibrate Therapy in Diabetes: Evidence Before FIELD. Curr Opin Lipidol. 2005;16(6):648-51. PubMed PMID: 16276243.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Role for fibrate therapy in diabetes: evidence before FIELD. A1 - Vergès,Bruno, PY - 2005/11/9/pubmed PY - 2008/8/22/medline PY - 2005/11/9/entrez SP - 648 EP - 51 JF - Current opinion in lipidology JO - Curr. Opin. Lipidol. VL - 16 IS - 6 N2 - PURPOSE OF REVIEW: Diabetic dyslipidaemia, among the main factors contributing to vascular risk in type 2 diabetes, is characterized by hypertriglyceridaemia, low HDL-cholesterol and increased prevalence of small dense LDL particles. Because fibrates have positive effects on triglycerides, HDL-cholesterol and LDL particle size, they may be an appropriate treatment for diabetic dyslipidaemia. Statins have been shown to diminish significantly the risk for coronary disease in patients with type 2 diabetes, and so what are the real effects of fibrates on cardiovascular risk in type 2 diabetes? RECENT FINDINGS: Although statins reduce the incidence of coronary disease in type 2 diabetes, data from clinical trials demonstrate 'residual' cardiovascular risk in these patients treated with statins. Clinical trials with fibrates show that they are particularly effective in reducing cardiovascular risk in patients with type 2 diabetes/metabolic syndrome and in those exhibiting the lipid abnormalities typical of diabetic dyslipidaemia (elevated triglycerides, low HDL-cholesterol). SUMMARY: Data on the effects of fibrates on cardiovascular risk in diabetes were obtained from subgroup analyses. Thus far, the only study performed specifically in patients with type 2 diabetes is the angiographic Diabetes Atherosclerosis Intervention Study which demonstrated a significant reduction in progression of atherosclerosis in patients receiving fenofibrate, but it was not powered to analyse the effects of fibrates on clinical outcomes. This is why the Fenofibrate Intervention and Event Lowering in Diabetes study is needed; it will provide robust data on the ability of fibrates to reduce cardiovascular risk in patients with type 2 diabetes. SN - 0957-9672 UR - https://www.unboundmedicine.com/medline/citation/16276243/Role_for_fibrate_therapy_in_diabetes:_evidence_before_FIELD_ L2 - http://Insights.ovid.com/pubmed?pmid=16276243 DB - PRIME DP - Unbound Medicine ER -